Main Industry
Biotechnology
Main Product/Service
Immunwork’s lead technology pipeline consists of ultra‑long‑acting peptides (via a fatty acid bundle platform), as well as antibody‑drug conjugates (ADCs) and antibody‑radionuclide conjugates (ARCs). These T‑E™ molecules leverage multi-arm linkers and tar
Founded Year
2014
Unified Business No.
24760917
Status
Active
Number of Employees
0
Total Paid-in
Capital
717,075,700 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Immunwork, Inc., founded in 2014 in Taipei, is a biotech company developing new drug entities using its proprietary T‑E™ pharmaceuticals platform, which integrates targeting (T) and effector (E) functions to enhance both efficacy and safety. The company i
Corporate Video
